XPO1 as a key regulator in small cell lung cancer: mechanisms, biomarkers, and therapeutic implications
Small cell lung cancer (SCLC) is a highly aggressive malignancy with limited treatment options. Despite advances in immunotherapy, response rates remain low, and the efficacy of current molecular subtyping[1][1],[2][2] is insufficient to predict therapeutic outcomes[3][3],[4][4]. A recently
Authors
- Dingzhi Huang (ORCID: https://orcid.org/0000-0002-2798-9459)
- Tingting Qin (ORCID: https://orcid.org/0000-0003-3810-7578)
- Jingya Wang (ORCID: https://orcid.org/0000-0002-2527-6121)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2025-06-27
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2025.0215
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City